<p><strong>Patients with renal impairment</strong>: Caution should be exercised in the treatment of patients with renal impairment and the dose should be adjusted according to creatinine clearance (CLCR) as follows:</p>

<ul>
	<li>CLCR &gt;60 ml/min: no dose adjustment required</li>
	<li>CLCR 30-60 ml/min: initial dose of 400 mg every other day for 2 weeks followed by a once daily dose of 400 mg.</li>
	<li>CLCR &lt;30 ml/min: use is not recommended in patients with severe renal impairment due to insufficient data</li>
</ul>

<p><strong>Patients with hepatic impairment</strong>: No dose adjustment is needed in patients with mild to moderate hepatic impairment. The pharmacokinetics of Eslicarbazepine acetate has not been evaluated in patients with severe hepatic impairment and use in these patients is therefore not recommended.</p>